Relevant aspects range from KRAS-dependent oncogenesis to mechanisms of resistance to KRAS inhibitors, epigenetics in KRAS mutant tumors, KRAS signaling in cancer immunity, and KRAS synthetic lethality. This evidence concerns the gene KRAS and cancer.